Home › Cancro al seno triplo negativo › Michigan › Grand Rapids
Studi clinici su Cancro al seno triplo negativo a Grand Rapids, MI
15 studi su Cancro al seno triplo negativo cercano partecipanti presso sedi a Grand Rapids e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
In reclutamentoFase 1
- South Texas Accelerated Research Therapeutics (START), Grand Rapids
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
In reclutamentoFase 1
- START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
In reclutamentoFase 1/2
- BAMF Health, Grand Rapids
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
In reclutamentoFase 3
- Cancer & Hematology Centers of Western Michigan ( Site 0026), Grand Rapids
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
In reclutamentoFase 1
- BAMF Health, Grand Rapids
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
In reclutamentoFase 1
- START Midwest, Grand Rapids
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
In reclutamentoFase 3
- Cancer and Hematology Centers of Western Michigan, Grand Rapids
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
In reclutamentoFase 1
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
In reclutamentoFase 1
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
In reclutamentoFase 1/2
- Research Site, Grand Rapids
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
In reclutamentoFase 1/2
- START Midwest, Grand Rapids
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
In reclutamentoFase 1/2
- START Midwest, Grand Rapids
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
In reclutamentoFase 1
- BAMF Health, Grand Rapids
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
In reclutamentoFase 1
- START Midwest, LLC, Grand Rapids
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
In reclutamentoFase 1
- START Midwest /ID# 248685, Grand Rapids
Studi su Cancro al seno triplo negativo in altre città
- Houston, TX42 studi
- New York City, NY31 studi
- Nashville, TN28 studi
- Los Angeles, CA27 studi
- Boston, MA26 studi
- San Antonio, TX23 studi
- St. Louis, MO21 studi
- Arlington, VA20 studi
- Atlanta, GA20 studi
- Dallas, TX18 studi
- Chicago, IL16 studi
- Columbus, OH16 studi
Altri studi a Grand Rapids
- Cancro del polmone non a piccole cellule44 studi
- Cancro colorettale40 studi
- Cancro (tutti i tipi)28 studi
- Cancro al seno26 studi
- Cancro ovarico24 studi
- Cancro metastatico22 studi
- Cancro alla prostata19 studi
- Cancro dell'endometrio18 studi
- Cancro dello stomaco18 studi
- Cancro pancreatico18 studi
- Melanoma17 studi
- Carcinoma a cellule squamose della testa e del collo15 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.